(University of Pennsylvania School of Medicine) Patients with the most common type of liver cancer who are taking the chemotherapy drug sorafenib can begin their treatment with a lower dose than is currently considered standard, and it will not affect how long they live when compared to patients who start on the full dose.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2w75Jbz
No comments:
Post a Comment